Our events

Evening of 5th March 2018

Nicox Conference & Cocktail

Meet the Management of Nicox, an international ophthalmology company, with two products approved for commercialization in the United States by licensed third parties, developing innovative solutions for maintaining vision and improving eye health. The company’s strategy is to maximize the potential of its research platform through internal developments and collaborations with leading pharmaceutical companies.

Registration

Evening of 21st March 2018

Transgene Conference & Cocktail

Transgene develops innovative immunotherapies against cancers and infectious diseases. Our approach aims to stimulate the immune responses of patients to attack diseased cells on multiple fronts. Five products are in Phase 1 to 3 of clinical trials. With our Invir.IOTM platform, we are designing a new generation of multifunctional oncolytic viruses. Meet our management to discuss our achievements of 2017 and prospects of 2018/2019.

Registration

Evening of 21st February 2018

Sensorion Conference & Cocktail

Meet the Management of Sensorion, a biotechnology company that develops first-in-class drugs for the treatment of inner ear diseases such as severe vertigo, tinnitus or hearing loss. There is still no cure for these highly disabling conditions that affect more than 140 million people worldwide and result in very high societal costs.

Registration

Evening of 30th January 2018

Evening of 30th January 2018

Cellnovo Conference & Cocktail

Meet the management of Cellnovo Group SA, a company that develops and distributes the world’s first all-in-one diabetes management system, including a ground-breaking insulin micro-pump. Cellnovo contributes to improving and simplifying the life of diabetic patients and participates in several major projects in the artificial pancreas.

Access to documents

Evening of 16th November 2017

Evening of 16th November 2017

Inauguration evening of Par'Immune

Par’Immune  is a biopharmaceutical company co-founded by Professor Monique Capron and Dr. Abderrahim Lachgar, dedicated to the development of an innovative drug candidate of parasitic origin, the P28GST. This candidate targeting autoimmune and inflammatory diseases is currently being evaluated in a Phase 2a clinical trial in patients with Crohn’s disease. In early 2018, the company will initiate its development plan to conduct two Phase 2b clinical trials in various inflammatory diseases.

Access to documents

EVENING OF 17th OCTOBER 2017

EVENING OF 17th OCTOBER 2017

PrimaDiag Conference & Cocktail

PrimaDiag is a French company developing and commercializing compact robotic platforms for the rapid automation of a wide variety of protocols in the field of molecular biology and genomics.

Access to documents


Diavein Conference Cocktail

Diavein is a start-up developing and marketing an electro-stimulation device of the vascular system. Diavein aims to relieve the sickle cell disease, the most common orphan genetic disease in the world (5 million people affected). It is characterized in particular by vaso-occlusive crises, due to obstructions of the blood vessels, very painful and too often fatal.

Access to documents

Evening of 3rd October 2017

Evening of 3rd October 2017

DEINOVE Conference & Cocktail

Presentation by the management of DEINOVE, a biotechnology company discovering, developing and producing compounds from the microbial world that are of interest to the health, nutrition and cosmetics industries.

It focuses on two major families of molecules: antibiotics and carotenoids (antioxidants) and collaborates in parallel with industrial groups seeking innovation.

Access to documents

Evening of 27th June 2017<br >BIOTECH AGORA<br >PRE-IPO, INVEST SECURITIES

Evening of 27th June 2017
BIOTECH AGORA
PRE-IPO, INVEST SECURITIES

NH TherAguix Conference & Cocktail

Presentation by the managemet of NH TherAguix,​​a pharmaceutical company developing innovative nanomedicine that improves the effectiveness of radiotherapy and reduces side effects without changing clinical practice. Its AGuIX® drug, in clinical phase 1, is a non-invasive, personalized solution that improves cancer imaging and treatment

Access to documents


Medsteer Conference & Cocktail

Presentation by the management of Medsteer, a company developing an innovative medical device for the anesthetists of the operating room. The EasyTIVA system, thanks to a patented algorithm based on cerebral activity, allows to regulate in real time the depth of the general anesthesia of the patient and to reduce the postoperative side effects. Patients wake up quickly and comfortably.

Access to documents

Evening of 23rd May 2017

Evening of 23rd May 2017

ERYTECH Conference & Cocktail

Presentation by the management of ERYTECH, a biopharmaceutical company in clinical stage that develops innovative therapies in rare forms of cancers and orphan diseases.

Based on its proprietary platform, ERYCAPS, which uses a new technology to encapsulate drugs (especially enzymes) in red blood cells, ERYTECH has developed a portfolio of candidate products addressing markets with strong medical needs.

Access to documents

Evening of 18th May 2017

Evening of 18th May 2017

Quantum Genomics Conference & Cocktail

Presentation by the management of Quantum Genomics, a company developing new therapies for unmet medical needs in the field of high blood pressure and heart failure.

During this evening, the managers will present the latest news of the company including the creation of the Shareholders’ Club.

Access to documents

Evening of 22nd February 2017

Evening of 22nd February 2017

LLTech Conference & Cocktail

Presentation by the management of LLTech, an innovative medical imaging company, specializing in real-time cancer diagnosis in the radiology and surgery room by CT SCAN OPTIQUE.

LLTech is already commercializing a system and is aiming for a $ 5 billion potential market with the development of a version intended for clinical routine in diagnosis (qualification of biopsies) and in cancer surgery (margins in real time).

Access to documents

Evening of 13th December 2016

Evening of 13th December 2016

Biophytis Conference & Cocktail

Presentation by the management of Biophytis, a company specializing in diseases related to the challenge of aging, especially those affecting muscular and visual functions.

It has a portfolio of first-in-class drug candidates to treat certain indications of sarcopenia and AMD, now without treatment.

Access to documents

Evening of 8th November 2016

Evening of 8th November 2016

Quantum Genomics Conference Cocktail

Meet the management of Quantum Genomics, a company developing new therapies for unmet medical needs in the field of high blood pressure and heart failure.

Access to documents

Evening of 5th July 2016

Evening of 5th July 2016

Cerenis Therapeutics Conference Cocktail

Meet Jean-Louis Dasseux, PhD, MBA, founder and CEO of Cerenis Therapeutics, inventor of innovative strategies based on HDL (the “good cholesterol”) for the treatment of cardiovascular and metabolic diseases.

Access to documents